MedTrace Logo

The Role of CK18F in Predicting Graft-Versus-Host Disease (GvHD)

NCT00935324 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2009-07-09

No results posted yet for this study

Summary

Prospective, within-subject controlled study on multiple subject groups to evaluate the meaning of CK18-fragments in the diagnosis, biological activity and prognosis of graft-versus-host disease (GvHD). Groups consist of patients scheduled for allogenic stem cell transplantation (allo-SCT) (Group A) and healthy voluntary blood donors (Group B).

Conditions

  • Allo-SCT

Sponsors & Collaborators

  • University of Regensburg

    collaborator OTHER

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Thomas Luft, MD · Heidelberg University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-03-31
Completion
2011-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00935324 on ClinicalTrials.gov